DOES THE DEFINTION OF BASELINE FEV1 FOR PULMONARY EXACERBATIONS AFFECT STUDY OUTCOMES IN PATIENTS WITH CYSTIC FIBROSIS?

被引：0
|
作者：
Schlag, F. [1 ]
Stanojevic, S. [1 ]
Waters, V. J. [1 ]
Tullis, D. E. [2 ]
Ratjen, F. [1 ]
机构：
[1] Hosp Sick Children, Toronto, ON, Canada
[2] St Michaels Hosp, Toronto, ON, Canada
来源：
PEDIATRIC PULMONOLOGY | 2017年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
456
引用
收藏
页码：S389 / S390
页数：2
相关论文
共 50 条
  • [31] Is FEV1 < 30% an indicator for lung transplantation in cystic fibrosis patients?
    Woo, MS
    PEDIATRIC TRANSPLANTATION, 2001, 5 (05) : 317 - 319
  • [32] Optimizing outcomes of pulmonary exacerbations in cystic fibrosis
    Szentpetery, Sylvia
    Flume, Patrick A.
    CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (06) : 606 - 611
  • [33] CHARACTERIZATION OF SERUM PROCALCITONIN AT BASELINE AND DURING PULMONARY EXACERBATIONS IN PATIENTS WITH CYSTIC FIBROSIS
    Maouelainin, N.
    Hoag, J. B.
    Hillman, J.
    Hendry, M. A.
    PEDIATRIC PULMONOLOGY, 2011, : 301 - 301
  • [34] Pulmonary Function (FEV1) in Cystic Fibrosis Patients with and without Severe Liver Disease with Portal Hypertension (CFLD)
    Polineni, D.
    VanderWyden, A.
    Hannah, W. B.
    Norris, S. A.
    Pace, R. G.
    Durie, P. R.
    Stonebraker, J. R.
    Schluchter, M. D.
    Knowles, M. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [35] Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1
    McColley, Susanna A.
    Konstan, Michael W.
    Ramsey, Bonnie W.
    Elborn, J. Stuart
    Boyle, Michael P.
    Wainwright, Claire E.
    Waltz, David
    Vera-Llonch, Montserrat
    Marigowda, Gautham
    Jiang, John G.
    Rubin, Jaime L.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (01) : 94 - 101
  • [36] Loss of FEV1 in cystic fibrosis: correlation with HRCT features
    Oikonomou, A
    Manavis, J
    Karagianni, P
    Tsanakas, J
    Wells, AU
    Hansell, DM
    Papadopoulou, F
    Efremidis, SC
    EUROPEAN RADIOLOGY, 2002, 12 (09) : 2229 - 2235
  • [37] Loss of FEV1 in cystic fibrosis: correlation with HRCT features
    Anastasia Oikonomou
    John Manavis
    Paraskevi Karagianni
    John Tsanakas
    Athol U. Wells
    David M. Hansell
    Frederica Papadopoulou
    Stavros C. Efremidis
    European Radiology, 2002, 12 : 2229 - 2235
  • [38] Understanding FEV1 for the purpose of cystic fibrosis registry comparisons: Does bias in annual review FEV1 affect between-centre comparison within the UK? An analysis of registry data
    Hoo, Zhe Hui
    Campbell, Michael J.
    Walters, Stephen J.
    Wildman, Martin J.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2020, 26 (01) : 229 - 235
  • [39] URINARY BIOMARKERS IN PATIENTS WITH CYSTIC FIBROSIS CORRELATE WITH FEV1 AND LUNG MICROBIOME DIVERSITY
    Vallieres, E.
    Parekh, G.
    Tunney, M. M.
    Einarsson, G. G.
    McGrath, S.
    McIlreavey, L.
    Johnston, E.
    Woolston, K.
    Downey, D.
    Davis, P.
    Elborn, J.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 268 - 268
  • [40] HOW MUCH FEV1 VARIABILITY CAN BE EXPLAINED BY PULMONARY EXACERBATIONS?
    Morgan, W. J.
    Millar, S.
    Pasta, D.
    Wagener, J.
    Konstan, M.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 375 - 376
12345